Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonistCHANGSHENG ZHENG; GANFENG CAO; MEI LI et al.Bioorganic & medicinal chemistry letters (Print). 2011, Vol 21, Num 5, pp 1442-1446, issn 0960-894X, 5 p.Article

Metabolism, Excretion, and Pharmacokinetics of [¹⁴C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in HumansSHILLING, Adam D; NEDZA, Frank M; SHEPARD, Stacey et al.Drug metabolism and disposition. 2010, Vol 38, Num 11, pp 2023-2031, issn 0090-9556, 9 p.Article

Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2XUE, Chu-Biao; ANLAI WANG; ANAND, Rajan et al.Bioorganic & medicinal chemistry letters (Print). 2010, Vol 20, Num 24, pp 7473-7478, issn 0960-894X, 6 p.Article

The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: Model characterization and applicationWONG, Harvey; GROSSMAN, Scott J; BAI, Stephen A et al.Drug metabolism and disposition. 2004, Vol 32, Num 12, pp 1359-1369, issn 0090-9556, 11 p.Article

DPC 681 and DPC 684: Potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variantsKALTENBACH, Robert F; TRAINOR, George; KLABE, Ronald et al.Antimicrobial agents and chemotherapy. 2001, Vol 45, Num 11, pp 3021-3028, issn 0066-4804Article